logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Novartis Pharmaceuticals Corporation drugs

    FiltersReset Filters
    68 results

    • adakveo

      (crizanlizumab)
      Novartis Pharmaceuticals Corporation
      Usage: ADAKVEO® is indicated for reducing the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 and older with sickle cell disease.

    • afinitor

      (everolimus)
      Novartis Pharmaceuticals Corporation
      Usage: AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

    • arranon - nelarabine injection

      (Nelarabine)
      Novartis Pharmaceuticals Corporation

    • arzerra - ofatumumab injection, solution

      (Ofatumumab)
      Novartis Pharmaceuticals Corporation

    • azopt - brinzolamide suspension/ drops

      (Brinzolamide)
      Novartis Pharmaceuticals Corporation

    • beovu

      (brolucizumab)
      Novartis Pharmaceuticals Corporation
      Usage: BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).

    • betoptic s

      (betaxolol hydrochloride)
      Novartis Pharmaceuticals Corporation
      Usage: BETOPTIC S (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

    • cipro

      (Ciprofloxacin Hydrochloride And Hydrocortisone)
      Novartis Pharmaceuticals Corporation

    • ciprodex - ciprofloxacin and dexamethasone suspension/ drops

      (Ciprofloxacin And Dexamethasone)
      Novartis Pharmaceuticals Corporation

    • coartem - artemether and lumefantrine tablet

      (Artemether And Lumefantrine)
      Novartis Pharmaceuticals Corporation
      • ...